The Motley Fool·2026-02-22 00:30Group 1: Natera - Natera represents 13.2% of the Duquesne Family Office holdings, with a market cap of $28.8 billion, specializing in genetic testing for women's health, oncology, and organ health [4] - The company is currently loss-making but is projected to have revenue growth at a high-teens percentage rate over the next couple of years, with a gross profit margin increasing from 61.8% in Q3 2024 to 64.9% in Q3 2025 [4] - Natera's oncology tests grew by 54% in Q3, making up 24% of total tests, and the bullish case for the stock is supported by its Signatera personalized blood test for detecting molecular residual disease in cancer patients [5][6] Group 2: Taiwan Semiconductor Manufacturing - Taiwan Semiconductor Manufacturing represents 5.4% of the portfolio and has seen an 80% increase over the last year, driven by AI spending [8] - The company reported robust AI-related demand in 2025, while non-AI markets showed only a mild recovery, indicating a dependency on AI spending for future prospects [9] - Capital spending is projected to exceed $101 billion over the next three years due to rising costs and growth support needs, which may limit free cash flow margin expansion opportunities [10][12]